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 ABSTRACT 
BACKGROUND:  Rett spectrum disorder is a progressive neurological disease and the 
most common genetic cause of mental retardation in females. MECP2, CDKL5, and 
FOXG1 have been found to be the causative genes. Each gene and different mutations 
within each gene contribute to variability in clinical presentation and several groups 
worldwide performed genotype-phenotype correlation studies using cohorts of patients 
with classic and atypical forms of Rett spectrum disorder. 
OBJECTIVE and METHODS: The Rett Networked Database is a unified registry of 
clinical and molecular data of Rett patients and it is currently one of the largest Rett 
registry worldwide with more than 1900 records provided by Rett expert clinicians from 
13 countries. 
RESULTS: Collected data revealed that the majority of MECP2 mutated patients 
present with the classic form, the majority of CDKL5 mutated patients with the early 
onset seizure variant and the majority of FOXG1 mutated patients with the congenital 
form. A computation of severity scores further revealed significant differences between 
groups of patients and correlation with mutation types. 
CONCLUSIONS: The highly detailed phenotypic information contained in the Rett 
Networked Database allow to group patients presenting specific clinical and genetic 
characteristics for studies by the Rett community and beyond. These data will also serve 
for the development of clinical trials involving homogeneous groups of patients.  
Keywords: patient registry, Rett syndrome, genotype-phenotype correlation. 
 
 INTRODUCTION 
Rett syndrome (RTT, OMIM 312750) is a severe X-linked neurodevelopmental disorder 
that affects predominantly females with an incidence of approximately 1 in 10,000 
female births. [1,2,3]. Classic RTT is infrequently observed in males because a 
deleterious mutation in the only copy of MECP2 typically results in severe neonatal 
encephalopathy and early lethality [4]. In the classic form, girls with RTT typically 
exhibit a relatively normal period of development for the first 6-18 months of life 
followed by a regression phase where patients lose acquired language and motor skill 
and exhibit intellectual disability and hand stereotypies. The hand stereotypies are typical 
in RTT and appear to be continuous, located predominantly over the anterior body 
midline [5]. Beyond the classic form of RTT, a number of atypical forms with different 
degrees of severity have been described: the Zappella variant (formerly known as 
preserved speech variant) [6,7], the infantile seizure onset type [8], the congenital form 
[9] and the ‘forme fruste’[10]. The Rett Networked Database (RND) is a registry of 
clinical and molecular data for patients affected by RTT [11]. Although it was initially 
targeting the European population of patients with RTT, it is now open to countries 
outside of Europe. RND is different from existing repositories for RTT clinical and 
molecular data [2,12,13]. First, RND records are updated by clinicians with experience 
in RTT. This is important to exclude potential bias existing when clinical data are 
gathered using questionnaires sent out to families by mail. Second, RND is among the 
largest RTT registries worldwide with more than 1900 patients on file. Third, RND is an 
open access initiative and data can be retrieved directly through a web-based search 
engine by interested professionals upon the submission of a research proposal to the 
Scientific Review Board [11] Public has access to general information and to content 
 description while the individual patient file can be granted only upon registration of 
physicians and clinical researchers in charge of specific patients. Here, we describe the 
first 1925 records contained in the registry and discuss the content of RND on the basis 
of the published guidelines for RTT clinical diagnosis. We analyzed the phenotype of 
patients with MECP2, CDKL5 and FOXG1 mutation to better understand the typical and 
atypical forms of RTT and provided information of RTT cohorts for the development of 
clinical trials. 
 
MATERIALS AND METHODS 
RND data 
RND contains clinical files for 1958 patients affected by classic or atypical RTT 
(numbers are given as of March 1st, 2017). Clinical data originates from Croatia (29 
patients), Denmark (64 patients), France (252 patients), Hungary (82 patients), India (3 
patients), Israel (93 patients), Italy (605 patients), Romania (15 patients), Serbia (50 
patients), Spain (398 patients), United Kingdom (255 patients), USA (96 patients) and 
Russia (16 patients). 
Statistical Analysis 
Differences in clinical characteristics between groups of patients were tested by Fisher's 
exact test or by chi-squared analysis when the normal approximation was appropriate. 
 
RESULTS 
Overview of RND data 
One thousand nine hundred fifty-eight patients with classic or atypical RTT are actually 
contained in RND. Among these, 1508 patients (77,0%) carry a mutation in a disease-
 causing gene while 450 patients (23%) do not show mutations in any of the gene linked 
to RTT syndrome. As expected, MECP2 is mutated in the majority of patients with 1404 
patients carrying a MECP2 mutation (93,1%). 78 patients carrying a mutation in CDKL5 
(5,2%) and 26 patients carrying a mutation in FOXG1 (1,7%), much less frequent causes 
of RTT syndrome. All cases are sporadic except for 2 pairs of sisters and 5 pairs of 
monozygotic twins affected by RTT and carrying a MECP2 mutation.  
Patients carrying a mutation in MECP2 
RND contains clinical files for 1404 patients carrying a mutation in the MECP2 gene. 
The mutation type and clinical variant type are available for 1141 patients (1131 females 
and 10 males). All mutation types are present in this population with early truncating and 
missense mutations being the most frequent mutations despite significant difference 
between classical and atypical forms (Table 1). A small percentage of patients (0,5%) 
has a mutation whose functional significance is unknown. This category includes 
synonymous mutations and intronic variants outside donor/acceptor splice sites 
potentially affecting the splicing of MECP2  and for which not enough functional data 
are available in order to support pathogenicity. These mutations are absent from the 
databases of variants identified in control individuals. Nine hundred twenty-one patients 
have the classic form of RTT (80,7%), 117 patients have the Zappella variant (10,3%), 
46 patients have the congenital variant of RTT (4%), seven patients have the early onset 
seizure variant (0,7%). Twenty-one patients (1,8%) do not fall into any of these 
categories because of the lack of one or several diagnostic criteria necessary for classical 
or atypical form classification. In addition, 19 patients (1,7%) are too young to be 
clinically defined as affected by the Zappella variant or the classical form. Criteria for 
the clinical diagnosis of RTT were last revised in RTT Diagnostic Criteria 2010 [14] in 
 order to include a regression period, partial or complete loss of acquired purposeful hand 
skills, stereotypic hand movements, partial or complete loss of acquired spoken language 
and gait abnormalities. We mined the RND data in order to investigate their compliance 
with the revised diagnostic criteria. Our analysis showed that, among the patients 
carrying a mutation in MECP2, regression occurred in 94,9% of patients, 90,6% lost or 
never acquired purposeful hand skills, 82,1% have stereotypic hand movements, 70,5% 
lost most or all spoken language and 74% have gait dyspraxia (Table 2). Notably, hand 
stereotypies, although considered an invariant clinical sign of classical RTT, are absent 
in 17,9% of MECP2 mutated patients included in the RND dataset.  On the other hand, 
the intense eye pointing phenotype of RTT patients, is present in 88% of MECP2 
positive cases (Table 2), although not included in the necessary criteria. RND data were 
further interrogated to define the most frequent clinical signs, i.e. clinical signs present in  
more than a 50% of MECP2 mutation carriers (Table 3). This analysis revealed that, in 
addition to the necessary criteria for RTT diagnosis, a normal head circumference at birth 
(93,5%) and a deficient sphincter control (88,7%) are main clinical signs in MECP2-
mutated patients. Interestingly, although 85,2% of the MECP2 positive patients have 
feeding difficulties (sometimes requiring gastrostomy), only half of them (53,6%) have 
gastrointestinal disturbances. This would suggest that part of the feeding difficulties arise 
from abnormal muscle tone and oropharyngeal dysfunction [15]. Even though breathing 
mechanisms in RTT preclinical models have been heavily investigated, breathing 
dysfunction "only" affects half (50%) of the patients carrying a mutation in MECP2. 
Interestingly, although loss of acquired speech is included among RTT diagnostic 
criteria, RND data show that the majority of MECP2 positive cases have never spoken 
(57,1%), as reported in Table 3. Among MECP2-mutated patients, it was possible to 
 compute the total score for 584 of the 1141 individuals for which the mutation status is 
available. This group included subjects over 5 years of age, and the most recent 
examination was used to compute the score. A cumulative distribution plots of patients 
positive for the MECP2 mutations is illustrated in Figure 1A and it is grouped on the 
basis of the four common point mutations (Arg106Trp, Arg133Cys, Thr158Met, 
Arg306Cys), the four early truncating mutations (Arg168*, Arg255*, Arg270*, 
Arg294*), late truncating mutations (LTM), large deletions and all other mutations. 
Although there is wide variability in clinical severity, there is a clear effect of specific 
common MECP2 point mutations on median clinical severity (Figure 1A). We indeed 
reported a case of 2 pairs of sisters carrying the same MECP2 mutation but with 
discordant clinical signs. One individual from each pair could not speak or walk, and had 
a profound intellectual deficit (classical RTT), while the other individual could speak and 
walk, and had a moderate intellectual disability (Zappella variant) [16]. The 5 
monozygotic twin pairs reported in RND, are much more concordant than the sister 
pairs. However, it is interesting to note that only 2 out of 5 twin pairs have an identical 
clinical score, indicating that at least at this level of investigation they are phenotypically 
identical. The 3 other twin pairs differ in specific fields such as epilepsy and weight 
(twin pair 1), level of speech and level of phrases (twin pair 2), or height, age of 
regression and voluntary hand use (twin pair 3). 
Patients carrying a mutation in CDKL5 
The phenotype of the patients carrying a mutation in CDKL5 and classified as having 
atypical RTT is much less documented than the classical RTT phenotype caused by 
MECP2 mutations. A report in 2013 described 86 patients with a mutation in CDKL5 
with data originating from family questionnaires [17]. RND contains 78 records for 
 CDKL5 mutation positive cases (76 females and 2 males). Similar to other records in 
RND, the clinical and molecular information were provided by experienced clinicians 
through direct patients’ evaluation. The cumulative distribution of the patients positive 
for CDKL5 mutations, clustered on the basis of early truncating mutations, late 
truncating mutations, large deletions, and missense mutations, is illustrated in Figure 1B. 
Forty-eight patients have the early onset seizure variant of RTT (85,7%), 1 patient has 
the Zappella variant (1,8%) and 1 patient has the congenital variant of RTT (1,8%). 
Mutation type is available for 65 patients. The most frequent mutations are truncating 
mutations (56,9%) followed by missense mutations (27,7%). In our cohort, the majority 
of patients have a normal head circumference at birth (94,9%), a deficient sphincter 
control (95,7%), feeding difficulties (97,4%), IQ < 40 (93,2%), presence of hand 
stereotypies (89,2%) and had never spoken (81,0%) (Table 3). Furthermore, epilepsy 
before 5 years of age is statistically significant among groups of patients (p-value 
<0.0001 MECP2 vs. CDKL5), since it is present in 100% of CDKL5 cases. The epilepsy 
started before 1 year of age in 95,7% of CDKL5 mutated patients versus 3,9% of MECP2 
mutated patients and 37,5% of FOXG1 mutated patients. Epilepsy is not controlled by 
therapy in 74,6% of CDKL5 cases versus 21,9% of MECP2 patients and 58,8% of 
FOXG1 mutated patients (Table 3). Involuntary movements, mood disturbances and 
breathing dysfunction are statistically less frequent in CDKL5 cases rather than in 
MECP2 or FOXG1 patients. Others features such as normal head circumference at birth, 
deficient sphincter controls, hand stereotypies, feeding difficulties, height and weight 
below the 25
th
 percentile and troubled night time sleeping are very similar among the 
three groups of patients carrying a MECP2, CDKL5 or FOXG1 mutation (Table 3). As 
for patients with MECP2 mutations, it was possible to compute the total score for 37 out 
 of 65 patients for which CDKL5 mutation status was available. This group included 
subjects with epilepsy onset occurring in early infancy for whom the most recent 
examination was used to compute the score. 
Patients carrying a mutation in FOXG1 
The phenotype of the patients carrying a mutation in FOXG1 and classified as having 
atypical RTT is even less documented than the phenotype caused by CDKL5 mutations. 
RND contains 27 records for FOXG1 mutation positive cases (19 females and 8 males). 
The full score is available for 26 patients. Twenty-three patients have the congenital form 
of RTT (88,5%), 1 patient has the classical form (3,8%), two do not fall into any of these 
categories (7,7%) because one or several necessary criteria for the diagnosis of classical 
or atypical forms were not present at the last examination (included in RND as "Rett-
like"). The cumulative distribution of the patients positive for FOXG1 mutations was 
obtained on the basis of early truncating mutations, late truncating mutations, gene 
deletions and missense mutations and it is illustrated in Figure 1C. In our cohort, all 
patients carrying a FOXG1 mutation had IQ < 40, microcephaly and no speech at 
examination (Table 3). Similarly, there is a significant overlap between the phenotype of 
patients with FOXG1 mutation and the phenotype of patients with MECP2 or CDKL5 
mutation. Eye pointing capability is reduced from 88% in MECP2 to 42% in CDKL5 and 
13,3% in FOXG1 patients. The percentage of patients having epilepsy before 5 years of 
age is 65,5%, 100% and 87,5% in the MECP2, CDKL5 and FOXG1 group of patients, 
respectively. However, only MECP2 versus CDKL5 and FOXG1 versus CDKL5 
comparisons were statistically significant. The percentage of patients that had a period of 
regression, IQ < 40, no speech at examination, scoliosis, breathing dysfunction and 
epilepsy not controlled by therapy is closer to the percentage observed for CDKL5 
 mutated patients rather than to the percentage observed for MECP2 patients. The major 
difference in the FOXG1 group is the higher percentage of patients that never learned to 
walk or speak or sit. About 92,3% of patients carrying a FOXG1 mutation has never 
spoken compared to the 57,1% of MECP2 and 81,0% of CDKL5 mutated patients. 
Moreover, FOXG1 mutated patients have never learned to sit (78,3%) and walk (91,3%) 
compared to MECP2 (12,9% and 31,7%) and CDKL5 (29,3% and 61,5%) respectively. 
The overall cumulative distribution plot of patients carrying a mutation in the MECP2, 
CDKL5 or FOXG1 genes is illustrated in figure 2. 
Patients without identified mutation 
Two hundred sixty-three patients (258 females and 5 males) have no identified mutation. 
Among these, 247 patients (242 females and 5 males) are negative after mutation 
screening of genes known to cause RTT phenotypes, 6 cases were not screened and the 
information is lacking for the remaining 10 patients. Although 120 patients are described 
as having classical RTT (46,7%) caution is needed in the consideration of such numbers.  
Indeed, although a majority of patients (89,2%) had a normal head circumference at birth 
and 88.6% have gone through a period of regression, only 46,8% of patients without 
mutation had hand stereotypies and 56,7% had never spoken. A third of these without a 
genetic aetiology (35%) had moderate to mild intellectual disability, when most MECP2 
or CDKL5 positive cases had an IQ below 40. The most frequent clinical characteristics 
of patients tested negative for MECP2, CDKL5 or FOXG1 mutation are presented in 
Table 4. Obviously, this is a most heterogeneous group and efforts are currently being 
done to add clinical data to the corresponding files and to increase the molecular 
screening output. 
 
 DISCUSSION 
Globally, the majority of RND patients do fulfill necessary criteria for the diagnosis of 
RTT with >70% of patients complying with the revised criteria [14]. A survey of the Rett 
syndrome Rare Disease Research Center (RDCRC) encompassing a population of 819 
patients diagnosed as having RTT and carrying a mutation in the MECP2 gene was 
published [18]. The mutation types in RND and RDCRC cannot be compared because 
the latter only presents the most frequent mutations and a global percentage of missense 
versus nonsense mutations is not provided. However, it is interesting to observe that both 
cohorts have a similar proportion of large deletions (8,7% in RDCRC and 8,5% in RND) 
in patient with classic RTT. However, a different percentage of classic RTT patients does 
not carry a mutation in MECP2 gene (5% in RDCRC and 11,2% in RND). Indeed, the 
RND population appears to be more clinically heterogeneous than the RDCRC cohort. 
For example, in RDCRC, 100% of the patients comply with the main criteria of RTT 
Diagnostic Criteria 2010 [14] necessary for typical or classic RTT (loss of hand use, loss 
of communication, hand stereotypies and gait abnormalities). In RND, the same criteria 
are present in 70,5% to 90,6% of classic RTT patients. Surprisingly, RND patients more 
frequently comply with the revised supportive criteria (all criteria present in > 45% 
patients) while one third supportive criteria are not found in the majority of RDCRC 
patients. RND is more "open" than RDCRC and patients can be included even if they do 
not meet one of the necessary criteria for the diagnosis of "classic" RTT. Based on our 
experience with more than 1900 patients originating from many different countries, we 
observed that the diagnosis of "classic RTT", made by the physicians at the moment of 
clinical files submission to the RND, does not perfectly comply with the RTT Diagnostic 
Criteria 2010. The RTT Diagnostic Criteria 2010 do not totally account for clinical 
 observations made by many specialists and these criteria will probably need to be 
adapted again in a near future. A large cohort (n=86) of patients with a mutation in 
CDKL5 was previously described based on the questionnaires collected by the 
InterRETT database [17]. RND provides the second largest cohort of patients harbouring 
a mutation in CDKL5 with 78 cases. Expectedly for the early seizure variant of RTT 
caused by CDKL5 mutations, the majority of patients experienced at least one episode of 
epilepsy (>90% in both cohorts). The proportion of patients with a mutation in CDKL5 
that never learned to walk in the two cohorts is also very similar (67,4% in InterRETT 
and 61,5% in RND), together with the proportion of patients displaying hand 
stereotypies (80,3% of females in InterRETT and 89,2% of patients positive for a 
mutation in CDKL5 in RND). There is a difference between the two cohorts concerning 
the speech skills, since 30 out of 76 females with CDKL5 mutation acquired early speech 
skills in the InterRETT cohort while only 5/42 females harbouring a CDKL5 mutation 
have acquired >10 words at age 5 in RND. In addition, another discrepancy concerns 
patients that had deceleration of head growth (59,5% in InterRETT and 29% in RND). 
An earlier study of the North American RTT Database relying on 914 patients with a 
mutation in MECP2 was published [13]. However, similar to the Australian database, the 
data relies on questionnaires sent out to families and even if the questionnaires were 
analyzed by experienced clinicians, the patients were not all directly examined by the 
contributors. Available results mainly concern molecular data with the distribution and 
nature of reported mutations. It does not contain CDKL5 or FOXG1 molecular data and 
does not provide details concerning the major phenotypic traits present in the studied 
population. In the Percy report [13], 85,5% of patients with MECP2 mutation have the 
typical form and 13,4% have the atypical form of RTT. Similarly, the percentage of 
 typical RTT patients with a MECP2 mutation in the RND is 80,7% when males and 
mutations of unknown significance are excluded. The cumulative distribution in Figure 
1A illustrates that there is a wide clinical variability within the same MECP2 mutation. 
However, the “mildest” mutations are Arg133Cys and late truncating mutations in 
accordance with previous reports [19]. The missense mutations Arg306, Thr158 and 
Arg106 (arginine or threonine can be replaced by any amino acid) and the early 
truncating mutation Arg294* belong to the intermediate severity phenotype. The 
remaining early truncating mutations (Arg168*, Arg255* and Arg270*) and large 
deletions are among the “most severe” form of RTT syndrome. It is interesting to note 
that the plot of each mutation is not always parallel. For example, Thr158Met and 
Arg294* move more vertical, suggesting that the phenotype of patients who have these 
mutations is less influenced by other genetic or environmental factors. The cumulative 
distribution in Figure 1B illustrates that a genotype-phenotype correlation for CDKL5 
may be barely recognized and the lines move together. It is interesting to note that late 
truncating mutations move less vertical, suggesting that the phenotype of patients who 
have these mutations is more variable. The cumulative distribution in Figure 1C shows a 
clear trend toward a less severe phenotype for FOXG1 late truncating mutations. The 
cumulative overall distribution in Figure 2 nicely illustrates the progressive severity 
going from MECP2 to CDKL5 and FOXG1 mutation. CDKL5 patients lie in the most 
severe range in comparison to MECP2 patients with FOXG1 patients even more shifted 
than CDKL5 patients towards a worse clinical phenotype and  a very minimum overlap 
with MECP2 patients. 
In conclusion, the Rett Networked Database is a registry for patients with RTT 
where clinical data are validated by experienced clinicians upon direct examination of 
 the affected individuals. One of the unique features of this database is its ability to 
collect a huge amount of clinical details, being almost 300 the collected clinical items 
with different levels of completeness, and genetic data [11]. It provides a unique resource 
in order to perform genotype-phenotype correlations. Overall, observation of RND data 
highlights clinical characteristics which occur more frequently in patients with a specific 
mutation (Table 3). For example, presence of regression and gait dyspraxia are 
statistically more frequent in MECP2 mutated patients; epilepsy and reduction in eye 
pointing capability are statistically more frequent in CDKL5 mutated patients, while the 
large majority of FOXG1 patients have never learned to walk, sit and speak. Moreover, 
we observed that the majority of MECP2 mutated patients have the classical form of 
RTT, the majority of CDKL5 mutated patients have the early onset variant and the 
majority of FOXG1 mutated patients have the congenital form, with some exceptions. 
The overlap between the different phenotypes is presented in Figure 3. RND provides an 
open structure, available to all interested professionals and a searchable web interface 
made available for registered users. These characteristics should prove useful to perform 
additional phenotype-genotype correlations, to better understand the typical and atypical 
forms of RTT, and to select adequate patient populations for future clinical trials. 
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 TABLES 
  
Table 1. MECP2 patients classified as classical or atypical RTT reported in RND  (total 
number of patients 1101). Cases below age 4 (n=19) are not taken into account here. 
Twenty-one patients do not fall into any of these categories because one or several 
necessary criteria for the diagnosis of classical or atypical forms were not present at last 
examination. In RND, early truncations are the mutations altering the MECP2 protein 
before amino acid 310. N represents the number of cases for which the corresponding 
item is present in the patient file, percentage is provided in brackets. 
Mutation Type 
Classic RTT 
N (%classical) 
Atypical RTT 
N (%atypical) 
Males 
N 
P-value 
classical vs. 
atypical RTT 
Total (%) 
Early truncating 404 (43,9) 36 (22) 3 <0,0001 443 (40,2) 
Missense 328 (35,7) 86 (50) 2 0,0002 416 (37,8) 
Late truncating 107 (11,6) 40 (23,2) 2 <0,0001 149 (13,5) 
Gene deletion 78 (8,5) 6 (3,6) 1 0,0264 85 (7,7) 
Gene duplication - 1 (0,6) 2 0,0199 3 (0,3) 
Unknown 
significance 
4 (0,3) 1 (0,6) - 0,7848 5 (0,5) 
  
  
  
  
  Table 2. Compliance of the RND data with the revised diagnostic criteria [14] for 
patients positive for a mutation in MECP2. Peripheral vasomotor disturbances are 
accounted for in the "Small cold hands and feet" score. The item "Diminished response 
to pain" is not present in RND data. N represents the number of cases for which the 
corresponding item is present in the patient file. N+ represents the number of cases 
positive for the clinical signs, percentage is provided in brackets. 
Clinical Sign N N+ (%) 
A period of regression 1189 1129 (94,9) 
NECESSARY CRITERIA   
Partial or complete loss of acquired purposeful hand 
skills 
961 871 (90,6) 
Stereotypic hand movements 1185 973 (82,1) 
Partial or complete loss of acquired spoken language 1039 733 (70,5) 
Gait abnormalities 700 518 (74,0) 
SUPPORTIVE CRITERIA   
Breathing disturbances when awake 1003 502 (50,0) 
Bruxism when awake 829 515 (62,1) 
Impaired sleep pattern 926 419 (45,2) 
Abnormal muscle tone - - 
Peripheral vasomotor disturbances - - 
Scoliosis or kyphosis 1189 754 (63,4) 
 Growth retardation* 1062 608 (57,3) 
Small cold hands and feet 1042 642 (61,6) 
Inappropriate laughing or screaming spells 560 171 (30,5) 
Diminished response to pain - - 
Eye pointing 958 843 (88,0) 
  
*Growth retardation was considered to be present when weight was below the 25th 
percentile. When height is considered, 61,6% (n=635) of MECP2 positive patients are 
below the 25th percentile. 
 Table 3. Main clinical characteristics in patients positive for a mutation in MECP2, CDKL5, and FOXG1. Clinical characteristics are listed 
in descending order of percentage of patients harbouring a mutation in MECP2. N represents the number of cases for which the 
corresponding item is present in the patient file. N+ represents the number of positive for the clinical sign, percentage is provided in 
brackets. P-value of significance is provided for comparison. 
Clinical Sign 
 
MECP2 
 
 
CDKL5 
 
 
FOXG1 
 
P-value 
MECP2 vs. 
CDKL5 
P-value 
MECP2 
vs. FOXG1 
P-value 
CDKL5 
vs. FOXG1 
  N N+ (%) N N+ (%) N N+ (%)       
A period of regression 1189 1129 
(94,9) 
61 27 
(44,3) 
25 13 
(52) 
<0,0001 <0,0001 0,5136 
Normal head 
circumference at birth 
900 842 
(93,5) 
39 37 
(94,9) 
17 14 
(82,4) 
0,7421 0,0663 0,1309 
Deficient sphincter 
control 
974 864 
(88,7) 
46 44 
(95,7) 
23 22 
(95,7) 
0,1409 0,2952 1 
Eye pointing 958 843 
(88,0) 
50 21  
(42) 
15 2 
(13,30) 
<0,0001 <0,0001 0,0417 
 Feeding difficulties 813 693 
(85,2) 
38 37 
(97,4) 
15 13 
(86,7) 
0,0364 0,8772 0,1288 
Presence of hand 
stereotypies 
1185 973 
(82,1) 
65 58 
(89,2) 
24 23 
(95,8) 
0,1414 0,0806 0,3338 
IQ < 40 916 701 
(76,6) 
59 55 
(93,2) 
24 24 
(100) 
0,0029 0,0069 0,191 
Microcephaly or 
deceleration of head 
growth 
1110 837 
(75,4) 
69 28 
(55,1) 
26 26 
(100) 
<0,0001 0,0037 <0,0001 
Gait dyspraxia 700 518 
(74,0) 
25 13 
(52,0) 
21 2  
(33,3) 
0,0146 <0,0001 0,0022 
No speech at 
examination 
1039 733 
(70,5) 
42 37 
(88,1) 
24 24 
(100) 
0,0138 0,0016 0,0787 
Epilepsy before 5 years 
of age 
689 451 
(65,5) 
64 64  
(100) 
16 14 
(87,5) 
<0,0001 0,0658 0,0042 
Scoliosis 1189 754 
(63,4) 
40 9  
(22,5) 
22 6  
(27,3) 
<0,0001 0,0033 0,6746 
Bruxism 829 515 
(62,1) 
49 21 
(42,9) 
17 11 
(64,7) 
0,0072 0,0782 0,0034 
 Height below the 25th 
percentile 
1031 635 
(61,6) 
42 20 
(47,6) 
25 17  
(68) 
0,0687 0,5147 0,1047 
Cold extremities 1042 642 
(61,6) 
41 16  
(39) 
22 10 
(45,5) 
0,0037 0,1236 0,6212 
Weight below the 25th 
percentile 
1062 608 
(57,3) 
46 22 
(47,8) 
25 17  
(68) 
0,2064 0,2825 0,1027 
Has never spoken 1039 593 
(57,1) 
42 34 
(81,0) 
26 24 
(92,3) 
0,0021 0,0003 <0,0001 
Involuntary movements 781 429 
(54,9) 
24 4  
(16,7) 
12 8  
(66,7) 
0,0002 0,4172 0,0027 
Gastrointestinal 
disturbances 
714 383 
(53,6) 
37 16 
(43,2) 
22 16 
(72,7) 
0,2165 0,0768 0,0279 
Mood disturbance 787 398 
(50,6) 
39 11 
(28,2) 
17 12 
(70,6) 
0,0064 0,1024 0,003 
Breathing dysfunction 1003 502 
(50,0) 
43 6  
(13,9) 
25 7  
(28) 
<0,0001 0,0294 0,1555 
Troubled night time 
sleeping 
964 431 
(44,7) 
62 27 
(43,5) 
18 11 
(61,1) 
0,8585 0,1658 0,189 
Never learned to walk 1180 374 65 40 23 21 <0,0001 <0,0001 0,0078 
 (31,7) (61,5) (91,3) 
Epilepsy not controlled 
by therapy 
1018 223 
(21,9) 
71 53 
(74,6) 
17 10 
(58,8) 
<0,0001 0,0003 0,1938 
Never learned to sit 1095 141 
(12,9) 
41 12 
(29,3) 
23 18 
(78,3) 
0,0025 <0,0001 0,0002 
Epilepsy before 1 years 
of age 
689 27  
(3,9) 
69 66 
(95,7) 
16 6  
(37,5) 
<0,0001 <0,0001 <0,0001 
  
 
 
 Table 4. Clinical characteristics in patients negative for mutation in MECP2, CDKL5 or 
FOXG1. The table is limited to the clinical characteristics present in more than 50% of 
these patients. N represents the number of cases for which the corresponding item is 
present in the patient file. N+ represents the number of positive for that clinical sign, 
percentage is provided in brackets. 
Clinical Sign 
 
MECP2 negative cases 
 
  N N+ (%) 
Deficient sphincter control 228 205 (90,0) 
Normal head circumference at birth 167 149 (89,2) 
A period of regression 245 217 (88,6) 
Regression of hand use 229 187 (81,7) 
Presence of epilepsy before age 5 216 166 (76,9) 
Microcephaly or deceleration of head 
growth 
229 159 (69,4) 
Bruxism 234 154 (65,8) 
IQ < 40 203 132 (65,0) 
Has never spoken 240 136 (56,7) 
  
  
 
  
  
 
Figure 1 A. Cumulative distribution plots of the patients positive for a MECP2 mutation. 
Mutations were grouped based on the four common point mutations (Arg106Trp, 
Arg133Cys, Thr158Met, Arg306Cys), the four early truncating mutations (Arg168*, 
A 
C 
B 
 Arg255*, Arg270*, Arg294*), late truncating mutations (LTM), large deletions and all 
other mutations. Early truncating mutations correspond to mutations interrupting the 
protein before amino acid 310. Large deletions correspond to deletions including either 
single exon or the entire gene. B. Cumulative distribution of the patients positive for a 
CDKL5 mutation. Mutations were grouped based as early truncating mutations 
(mutations interrupting protein before amino acid 297), late truncating mutations, large 
deletions (deletions involving either single exons or the entire gene), and missense 
mutations. C. Cumulative distribution of the patients positive for a FOXG1 mutation. 
Mutations were grouped based as early truncating mutations (mutations interrupting 
protein before amino acid 275), late truncating mutations, gene deletions (deletions 
involving either single exons or the entire gene), and missense mutations. 
 
 
Figure 2 Combined graph illustrating the different clinical severities between MECP2, 
CDKL5, and FOXG1 mutated patients. 
  
Figure 3 Genotypes and phenotypes in RND. The majority of MECP2 mutated patients 
(light blue) have the classical form (triangles), the majority of CDKL5 mutated patients 
(green) have the early onset seizure variant (stars) and the majority of FOXG1 mutated 
patients (pink) have the congenital form (crosses). Several exceptions to this rule are 
present: among the MECP2 mutated patients (light blue) about 6% have the Zappella 
variant (dots), about 2% has the congenital variant of RTT (crosses), and about 0,4% 
have the early onset seizure variant (stars); among the CDKL5 mutated patients (green) 
about 1,8% patients have the Zappella variant (dots) and another 1,8% have the 
congenital form (crosses); among the FOXG1 mutated patients (pink) about 5% of 
patients has the classical form (triangles) [2]. 
  
